Virology and Bacteriology

Global Virology and Bacteriology Market to Reach US$2.7 Billion by 2030

The global market for Virology and Bacteriology estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Molecular Diagnostics Technology, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Immunoassays Technology segment is estimated at 3.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$588.9 Million While China is Forecast to Grow at 7.2% CAGR

The Virology and Bacteriology market in the U.S. is estimated at US$588.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$550.9 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Virology and Bacteriology Market - Key Trends & Drivers Summarized

How Are Virology and Bacteriology Shaping the Foundation of Modern Infectious Disease Science?

Virology and bacteriology, the scientific disciplines focused on the study of viruses and bacteria respectively, form the bedrock of infectious disease research and response. Together, they provide critical insights into the structure, function, genetics, and behavior of the microorganisms responsible for the vast majority of global health threats. Over the past few decades, advances in molecular biology and genomic sequencing have dramatically enhanced the ability to detect, characterize, and understand these pathogens. This deeper understanding has proven vital not only for the development of vaccines and antimicrobial therapies but also for the formulation of public health strategies aimed at outbreak containment and prevention. The COVID-19 pandemic underscored the importance of virological research, while the ongoing global challenge of antimicrobial resistance (AMR) has refocused attention on bacteriological surveillance and antibiotic development. Both fields contribute substantially to early warning systems, enabling the identification of zoonotic spillovers and emerging infections before they reach pandemic proportions. Additionally, ongoing work in bacteriophage research and viral vector applications is blurring the traditional boundaries between the two disciplines, highlighting their interconnectedness in therapeutic innovation. From lab-based diagnostics to epidemiological modeling and vaccine design, virology and bacteriology remain essential to confronting old and new microbial threats in an increasingly interconnected world. As pathogens evolve, so too must the scientific tools and collaborative networks that study them, making continued investment in these fields a cornerstone of global health security.

What Technological Innovations Are Driving Advances in Virology and Bacteriology Research?

The fields of virology and bacteriology have been revolutionized by a wave of technological innovations that are enabling faster, more accurate, and more comprehensive research. One of the most transformative developments is next-generation sequencing (NGS), which allows scientists to decode the entire genomes of viruses and bacteria in a matter of hours. This technology facilitates rapid identification of novel pathogens, tracks the evolution of resistance genes, and supports real-time surveillance of infectious disease outbreaks. In parallel, CRISPR-based gene editing tools are being used to dissect microbial genomes and understand host-pathogen interactions at an unprecedented level of detail. Proteomics, transcriptomics, and metabolomics are further expanding the toolkit for understanding how pathogens function and interact with their hosts. On the diagnostic front, portable PCR machines, biosensors, and point-of-care tests are drastically reducing the time required to identify infectious agents in clinical and field settings. Artificial intelligence and machine learning algorithms are also being used to predict outbreak trends, model drug-target interactions, and assist in the design of vaccines and therapeutics. In laboratory environments, high-throughput screening technologies are allowing researchers to test thousands of compounds against bacteria and viruses simultaneously, accelerating the discovery of new antimicrobials and antivirals. These technological advances are not only making research more efficient but are also democratizing it by making tools more accessible to laboratories around the world. As innovation continues, virology and bacteriology are expected to become even more integrated with digital health and systems biology, enabling a more proactive and personalized approach to infectious disease management.

Why Are Virology and Bacteriology Central to Addressing Global Health Challenges?

In the face of rising global health threats, the roles of virology and bacteriology have become increasingly central to ensuring public health preparedness and response. Infectious diseases remain one of the leading causes of morbidity and mortality worldwide, particularly in low and middle-income countries. Viral diseases such as HIV, hepatitis, influenza, and more recently, COVID-19, continue to place a heavy burden on healthcare systems and economies. On the other hand, bacterial infections such as tuberculosis, pneumonia, and sepsis remain persistent killers, especially as antimicrobial resistance renders many first-line antibiotics ineffective. Understanding the biology, transmission, and evolution of these pathogens is crucial to developing effective interventions. Virology provides the framework for creating antiviral therapies and designing vaccines, while bacteriology supports the development of antibiotics, probiotics, and infection control protocols. Additionally, the synergy between the two fields is vital in tackling co-infections, such as viral-bacterial pneumonia or HIV-associated tuberculosis. Virology and bacteriology also contribute significantly to veterinary and agricultural health, influencing zoonotic transmission and food safety practices. In humanitarian and emergency contexts, these sciences support outbreak detection and control, minimizing the impact of disease in vulnerable populations. With the increasing incidence of emerging infectious diseases and the globalization of trade and travel, the role of virologists and bacteriologists extends far beyond the laboratory. Their work underpins global initiatives for disease eradication, pandemic preparedness, and the development of resilient healthcare systems capable of responding to evolving microbial threats.

What Market Forces and Policy Initiatives Are Driving Growth in Virology and Bacteriology Sectors?

The growth in the virology and bacteriology market is driven by multiple factors that reflect the growing urgency of infectious disease management, rising investments in healthcare infrastructure, and policy-level commitments to global health security. A major driver is the increasing incidence of infectious disease outbreaks and the heightened awareness of pandemic risks following COVID-19. Governments, health organizations, and funding bodies are allocating more resources to research, surveillance, and diagnostic development, creating new opportunities for companies and academic institutions specializing in microbial science. Another important factor is the intensification of antimicrobial resistance, which has spurred initiatives by the World Health Organization, the Centers for Disease Control and Prevention, and the European Union to support new antibiotic pipelines and stewardship programs. Additionally, the expansion of biotechnology and pharmaceutical sectors is fostering collaborations that bring together expertise in virology and bacteriology for the development of vaccines, therapeutics, and diagnostics. The rise in global travel and trade is also prompting the establishment of regional disease surveillance hubs and laboratory networks that depend heavily on skilled virology and bacteriology personnel. Regulatory agencies are streamlining approval processes for new technologies in response to urgent public health needs, further accelerating innovation in the sector. Educational institutions are also expanding their programs to produce a new generation of microbiologists equipped to tackle modern challenges. These dynamics are being reinforced by public-private partnerships and international collaborations that aim to harmonize data sharing, research priorities, and funding mechanisms. As infectious disease continues to dominate global health agendas, virology and bacteriology will remain indispensable disciplines at the center of both policy and practice.

SCOPE OF STUDY:

The report analyzes the Virology and Bacteriology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Molecular Diagnostics Technology, Immunoassays Technology, Diagnostic Imaging Technology, Information Technology); End-Use (Hospitals End-Use, Diagnostic Centers End-Use, Research Laboratories End-Use, Blood Banks End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Abbott Laboratories
• Agilent Technologies Inc.
• Becton, Dickinson and Company
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Bruker Corporation
• Cepheid (Danaher)
• Charles River Laboratories
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• Illumina, Inc.
• Lonza Group AG
• Merck KGaA
• PerkinElmer, Inc.
• QIAGEN N.V.
• QuidelOrtho Corporation
• Shimadzu Corporation
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• ZEISS Group

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.